InMed Pharmaceuticals News | Press Releases

Skip to content

Facebook Twitter Linkedin

Pharmaceutical
Manufacturing
Investors
Corporate
Learn

Pharmaceutical
Manufacturing
Investors
Corporate
Learn

Press Releases

InMed Pharmaceuticals, Inc. Appoints Senior Vice President, Clinical and Regulatory Affairs

October 31, 2016

InMed Pharmaceuticals, Inc. Closes Non-Brokered Private Placement for C$1,500,000

October 27, 2016

InMed Pharmaceuticals, Inc. Announces Non-Brokered Private Placement of C$1,500,000

October 4, 2016

InMed Appoints Andrew Hull to the Board of Directors

September 13, 2016

InMed to Present at 18th Annual Rodman and Renshaw Global Investment Conference

September 12, 2016

InMed Pharmaceuticals, Inc. Closes Non-Brokered Private Placement for C$304,500

July 28, 2016

InMed Pharmaceuticals, Inc. Announces Non-Brokered Private Placement of C$250,000

July 19, 2016

InMed Announces Appointment of Eric A. Adams as CEO, President and Director

June 16, 2016

InMed Announces Appointment of William J. Garner, M.D. to its Board of Directors

June 13, 2016

InMed Updates Progress of its Epidermolysis Bullosa Program

May 18, 2016

InMed Pharmaceuticals Provides Strategic Update on its Business Plans, Announces Planned Executive and Board Departures

May 4, 2016

InMed Announces Update on Biosynthesis Project

February 16, 2016

InMed Strengthens Board with Appointment of Experienced Biotech Executive Adam Cutler

November 23, 2015

InMed Provides Update on Progress of its Development Program for Epidermolysis Bullosa

November 4, 2015

InMed Pharmaceuticals, Inc. Announces Non-Brokered Private Placement for up to C$1,000,000

November 2, 2015

InMed Appoints Paul Brennan as President & Chief Executive Officer

September 3, 2015

InMed Commences Development of Proprietary Drug Delivery System

September 2, 2015

InMed Appoints Paul Brennan to the Board of Directors

August 25, 2015

InMed Pharmaceuticals Announces Progress in Orofacial Pain Program

August 20, 2015

InMed Announces Positive In-Vitro Study Results of INM-750 Targeting Epidermolysis Bullosa Simplex (EBS)

August 6, 2015

« Previous Page1 Page2 Page3 Page4 Page5 Page6 Page7 Page8 Page9 Page10 Page11 Page12 Page13 Page14 Next »

Management

Board of Directors

Scientific Advisory Board

Investor Alerts

Sign up to receive news releases from InMed Pharmaceuticals.

#1455 – 885 West Georgia St.
Vancouver, BC, Canada
V6C 3E8

Pharmaceutical

INM-901 for Alzheimer’s Disease
INM-089 for Age-related Macular Degeneration
INM-755 for Epidermolysis Bullosa
INM-088 for Glaucoma
Novel Analogs

MANUFACTURING

BayMedica – Rare Cannabinoid Ingredients
Cannabinoid Manufacturing Expertise
IntegraSyn™ Cannabinoid Manufacturing

Investor

News
Events
Stock Information
Corporate Governance
Financials & AGM Materials
Filings
Presentations
Media & Videos
Investor Contact

CORPORATE

Management
Board of Directors
Scientific Advisors
Partners and Collaborators
Careers
Contact

Learn

What is Cannabinol (CBN)?
What is Epidermolysis Bullosa (EB)?
What is Glaucoma?
Cannabinoid Manufacturing Economics 101
GMP Manufacturing Standards by Product Type
Cannabinoids for Glaucoma
Cannabinoid Science
Articles and Videos

© Copyright 2025 InMed Pharmaceuticals Inc.

Privacy Policy
Terms of Use
Legal Disclaimer

Find Us On:

Sign up to receive emails from InMed Pharmaceuticals

"*" indicates required fields

Name*

First name* Last name*

Email*

Consent*

By providing your e-mail address, you consent to receive news, press releases, quarterly and annual reports, presentations and other information from InMed Pharmaceuticals Inc. You can unsubscribe at any time.

CAPTCHA